| First Author | Zhang H | Year | 2021 |
| Journal | J Comp Neurol | Volume | 529 |
| Issue | 15 | Pages | 3497-3512 |
| PubMed ID | 34212389 | Mgi Jnum | J:350021 |
| Mgi Id | MGI:6794101 | Doi | 10.1002/cne.25207 |
| Citation | Zhang H, et al. (2021) ErbB4 mediates amyloid beta-induced neurotoxicity through JNK/tau pathway activation: Implications for Alzheimer's disease. J Comp Neurol 529(15):3497-3512 |
| abstractText | Accumulation of amyloid beta (Abeta) in the brain is a hallmark of Alzheimer's disease (AD). We previously showed that ErbB4 in parvalbumin (PV)-positive interneurons was associated with Abeta-induced cognitive deficits; however, the underlying mechanism remains undetermined. Here we found that specific deletion of ErbB4 in PV neurons significantly attenuated oligomeric Abeta-induced neuronal toxicity and inhibited Abeta-induced decreases of PSD95 and synaptophysin. Moreover, specific ablation of ErbB4 in PV neurons altered activity-related protein c-Fos and decreased hippocampal PV neurons, especially in the dentate gyrus (DG) of hAPP-J20 mice. Furthermore, c-Jun N-terminal kinase (JNK), a protein downstream of ErbB4, was activated by Abeta but not ErbB4's ligand neuregulin 1 (NRG1) beta1, suggesting different downstream pathways for Abeta and NRG1beta1. JNK phosphorylation was inhibited by the ErbB4 inhibitor AG1478 and by pretreatment with NRG1beta1. More importantly, siRNA knockdown of ErbB4 decreased JNK phosphorylation and expression, tau phosphorylation at Ser396 and Thr 205, and Bax expression. Therefore, ErbB4 might mediate Abeta-induced neuropathology through the JNK/tau pathway and represent a potential therapeutic target in patients with AD. |
